Sector News

Stryker acquires intensive-care product maker for $2.76 billion

February 3, 2016
Life sciences

Medical-device maker Stryker reached a deal to buy a 45-year-old manufacturer of health-care treatment products for hospitals for $2.76 billion.

Stryker is acquiring Sage Products from private equity firm Madison Dearborn Partners, the companies said in a statement Monday.

Cary, Ill.-based Sage, which had $430 million in revenue in its 2015 fiscal year, makes disposal products aimed primarily at intensive-care units and other hospital settings. Its products include solutions for patient cleaning, turning and positioning, oral care and skin preparation. Stryker sells products that are complementary to those produced by Sage, the companies said.

Stryker, based in Kalamazoo, Mich., said it would glean a $500 million tax benefit from the deal, which is expected to close in the second quarter.

“This acquisition aligns with Stryker’s focus on offering products and services that support a mindset of prevention, specifically in the area of ‘never events’ such as hospital-acquired infections,” Stryker CEO Kevin Lobo said in a statement.

Stryker raised its full-year 2016 earnings projection by 5 cents per share to a range of $5.55 to $5.75.

By Nathan Bomey

Source: USA Today

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach